First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

[1]  J. Pérez-Ruixo,et al.  Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients , 2011, Cancer Chemotherapy and Pharmacology.

[2]  Juan A. Bueren-Calabuig,et al.  Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. , 2009, Biochemical pharmacology.

[3]  Y. Pommier,et al.  Zalypsis (PM00104) is a potent inducer of γ-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition , 2009, Molecular Cancer Therapeutics.

[4]  J. Baselga,et al.  Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Lepage,et al.  Abstract #2018: Antitumor activity of PM00104 in hepatocellular carcinoma (HCC) experimental models , 2009 .

[6]  X. Chen,et al.  Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. , 2009, Blood.

[7]  R. Plummer,et al.  179 POSTER Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma , 2008 .

[8]  D. Lepage,et al.  Antitumor activity of Zalypsis® (PM00104) in experimental models of bladder, gastric and liver cancer. , 2007 .

[9]  A. Maier,et al.  Preclinical evaluation of PM00104 to support the selection of tumor indications for clinical development , 2007 .

[10]  S. Moreno,et al.  Genome-wide screen reveals antitumor Zalypsis® as a strong inducer of DNA double strand breaks , 2007 .

[11]  M. Kris,et al.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Munt,et al.  Toxicokinetic evaluation of a novel anti-tumor agent, Zalypsis® (PM00104), in dogs , 2006 .

[13]  高橋 聡,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v3.0による胃癌術後合併症の解析 , 2006 .

[14]  M. Elices,et al.  The novel compound PM00104 exhibits significant in vivo activity against breast tumors. PM00104 exhibits significant in vivo activity against breast tumors , 2005 .

[15]  S. Munt,et al.  Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM00104, a novel antineoplastic agent, in mouse, rat, dog, and human plasma. , 2005, Rapid communications in mass spectrometry : RCM.

[16]  S. Matsunaga,et al.  Renieramycin J, a highly cytotoxic tetrahydroisoquinoline alkaloid, from a marine sponge Neopetrosia sp.. , 2003, Journal of natural products.

[17]  A. Fontana,et al.  A New Antitumor Isoquinoline Alkaloid from the Marine Nudibranch Jorunna funebris , 2000 .

[18]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[19]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[20]  Paul A. Keifer,et al.  Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata , 1990 .

[21]  Groupe Coopérateur Des Leucémies et Hématosarcomes.  Essai de recherche d'efficacité de l'association de prednisone, vincristine, méthyl-glyoxal-bis (guanylhydrazone) (méthyl-GAG) et méthotrexate sur les leucémies aiguës monoblastiques , 1970 .